Online citations, reference lists, and bibliographies.
← Back to Search

Miastenia Grave: Avaliação Clínica De 153 Pacientes

F. M. Cunha, R. Scola, L. C. Werneck
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
We have retrospectively analysed the records of patients diagnosed as having myasthenia gravis and followed up in our departament from February 1973 to March 1995. The main clinical findings were ptosis, diplopia, dysphagia, disphonia or dysarthria, mastigatory impairment, dyspnea, asthenia, weakness of the cervical muscles and of the extremities, as well as findings of the physical and neurological examination. Based on the information collected, the patients were classified clinically according the modified Osserman-Gerkins scale, but considering the non-dynamic aspects of that scale, we used the modified functional scale of Niakan and classified the patients clinically as follows: remission, controled, stable, partially controled, poorly controled, no response. We collected 153 patients, 104 (68.0%) females and 49 (32.0%) males producing a female/male ratio of 2.2:1. The duration of the disease varied from seven days to 27 years, mean 6.26 years (±5.44). Age at the first symptoms varied between 24 hours to 80 years, mean of 32.13 years (±19.48). We had 30 patients ranging from 0 to 15 years of age, 91 patients were observed between 15 and 50 years and 32 patients after the age of 50 years. Above the age of 60 years, the disease aflicts males more than females with a ratio of 1.5:1. The acquired auto-immune form with generalized weakness was the most frequent presentation. However, ocular muscle weakness with ptosis and diplopia were the most commom clinical presentation in our series.
This paper references
10.1001/ARCHNEUR.1986.00520020049018
Immunosuppressive drug therapy in myasthenia gravis.
E. Niakan (1986)
10.1212/WNL.41.9.1497
Inflammation at the neuromuscular junction in myasthenia gravis
R. Maselli (1991)
10.1016/0022-510X(83)90095-3
Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 1. Relation to clinical parameters in 250 patients
P. Limburg (1983)
10.1111/j.1749-6632.1981.tb33764.x
THE NATURAL COURSE OF MYASTHENIA GRAVIS AND EFFECT OF THERAPEUTIC MEASURES
D. Grob (1981)
10.1212/WNL.40.11.1663
Why are eye muscles frequently involved in myasthenia gravis?
H. Kaminski (1990)
10.1177/003693306000501001
Myasthenia Gravis: A New Hypothesis
J. Simpson (1960)
10.1016/S0733-8619(18)30097-5
Acquired myasthenia gravis. Immunopathology.
D. Richman (1994)
10.1002/MUS.880161210
Acetylcholine receptor subunit gene expression in thymic tissue
H. Kaminski (1993)
Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.
K. Osserman (1971)
10.1001/ARCHPEDI.1981.02130270001001
Neonatal myasthenia gravis.
C. Barlow (1981)
10.1080/21548331.1993.11442741
Autoimmune myasthenia gravis.
G. Lopate (1993)
10.1212/WNL.43.9.1779
Incidence and prevalence of myasthenia gravis in western Denmark
P. Christensen (1993)
10.1080/21548331.1980.11946648
Welcome, Class of 1984
H. Morowitz (1980)
10.1001/ARCHNEUR.1971.00490010059009
Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families.
T. Namba (1971)
10.1212/WNL.44.7.1208
Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis
P. I. Andrews (1994)
10.1126/science.180.4088.871
Autoimmune Response to Acetylcholine Receptor
J. Patrick (1973)
10.1001/ARCHNEUR.1991.00530190081019
Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.
F. Somnier (1991)
10.1016/S0733-8619(18)30104-X
Congenital myasthenic syndromes.
A. Engel (1988)
10.1212/WNL.31.4.476
Myasthenia gravis in infancy
M. Seybold (1981)
10.1136/jnnp.56.5.496
Clinical implementation of anti-acetylcholine receptor antibodies.
F. Somnier (1993)
10.1590/S0004-282X1987000400004
[Myasthenia gravis. Clinical and therapeutic evaluation of 55 cases].
L. Werneck (1987)
10.1212/WNL.42.10.1888
The epidemiology of myasthenia gravis in central and western Virginia
L. H. Phillips (1992)
10.1111/j.1600-0404.1991.tb04654.x
Comparative study on the prevalence of myasthenia gravis in the provinces of Bologna and Ferrara, Italy
R. D'alessandro (1991)
10.1002/MUS.880160505
α‐Bungarotoxin sensitization in experimental autoimmune myasthenia gravis
P. Kennel (1993)
10.1212/WNL.40.5.786
The relationship of age to outcome in myasthenia gravis
D. Donaldson (1990)
New experimental autoimmune models.
E. Mozes (1989)
10.3181/00379727-105-26051
Immunofluorescence Demonstration of a Muscle Binding, Complement-Fixing Serum Globulin Fraction in Myasthenia Gravis. ∗
A. Strauss (1960)
10.1212/WNL.48.Suppl_5.36S
The clinical limits of myasthenia gravis and differential diagnosis
R. Lisak (1997)
10.1111/j.1600-0404.1989.tb03793.x
Epidemiological study of myasthenia gravis in Sardinia, Italy (1958–1986)
M. Giagheddu (1989)
10.3181/00379727-105-26050
Changes in Serum Complement Activity in Patients with Myasthenia Gravis. ∗
W. L. Nastuk (1960)
10.1590/S0004-282X1991000400007
Miastenia grave tratamento clínico x cirúrgico
L. C. Werneck (1991)
10.1016/S0733-8619(18)30095-1
Clinical features of myasthenia gravis.
L. Hopkins (1994)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar